These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19764104)

  • 1. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
    Huang WS; Yang CH
    World J Gastroenterol; 2009 Sep; 15(35):4464-6. PubMed ID: 19764104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All that glitters: sorafenib.
    Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
    Intern Med; 2011; 50(7):797. PubMed ID: 21467725
    [No Abstract]   [Full Text] [Related]  

  • 3. A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
    Joshita S; Yoshizawa K; Sano K; Kobayashi S; Sekiguchi T; Morita S; Kamijo A; Komatsu M; Umemura T; Ichijo T; Matsumoto A; Tanaka E
    Intern Med; 2010; 49(11):991-4. PubMed ID: 20519814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.
    Shiozawa K; Watanabe M; Takenaka H; Nagai H; Ishii K; Sakai K; Sumino Y
    Hepatogastroenterology; 2010; 57(101):688-90. PubMed ID: 21033210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
    Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G; Paggi S
    N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract]   [Full Text] [Related]  

  • 7. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 8. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 9. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
    Dogan E; Aksoy S; Arslan C; Dede DS; Altundag K
    Med Oncol; 2010 Dec; 27(4):1436-7. PubMed ID: 20012235
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib-induced destructive thyroiditis.
    Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
    Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
    Yau T; Chan P; Ng KK; Chok SH; Cheung TT; Fan ST; Poon RT
    Cancer; 2009 Jan; 115(2):428-36. PubMed ID: 19107763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
    Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
    Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
    [No Abstract]   [Full Text] [Related]  

  • 14. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
    Kim SO; Han SY; Baek YH; Lee SW; Han JS; Kim BG; Cho JH; Nam KJ
    World J Gastroenterol; 2011 Jan; 17(2):267-70. PubMed ID: 21246003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
    Keating GM; Santoro A
    Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib: in hepatocellular carcinoma.
    Simpson D; Keating GM
    Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
    Rombolà F; Caravetta A; Mollo F; Spinoso A; Peluso L; Guarino R
    Acta Medica (Hradec Kralove); 2011; 54(4):177-9. PubMed ID: 22283115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib for treatment of hepatocellular carcinoma: a systematic review.
    Xie B; Wang DH; Spechler SJ
    Dig Dis Sci; 2012 May; 57(5):1122-9. PubMed ID: 22451120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.